Press releases
September 30, 2021
HTL launches a new bioproduction unit HTL4
Representing an investment of more than 50 million euros, this new unit dedicated to the bioproduction of pharmaceutical-grade hyaluronic acid represents a pivotal stage in the development of HTL and the largest investment ever made in the world for a biopolymer production unit.
It will enable HTL to become the largest producer of pharmaceutical-grade hyaluronic acid in the world and accelerate its international development.
Read more below.
To see our most recent news,
Read more
news from us
-
Articles October 3, 2024HTL Biotechnology will launch its White Paper at CPHI Milan!
We are excited to announce that the HTL Biotechnology team will be attending CPHI Milan and on this occasion, we will be launching our White Paper to celebrate 90 years of discovery of Hyaluronic Acid!
-
Articles October 1, 2024New Certification for HTL Biotechnology
We are proud to announce that HTL Biotechnology has recently received Halal certification for two of our key products: DNA and HANa.
-
Articles July 5, 2024HTL Biotechnology Secures Medical Device Registration in China
Sodium DNA Raw Material Main Document (Polynucleotides) registered as a medical device (number M2024199-000) in China.